FDA Approves LENALIDOMIDE — Alvogen, Inc.

# FDA Approves Generic Lenalidomide from Alvogen Alvogen, Inc. has received FDA approval for generic lenalidomide, an oral immunomodulatory drug used to treat multiple myeloma and other blood cancers, potentially opening the market to lower-cost alternatives and increasing competition in a segment currently dominated by Celgene's branded Revlimid. The approval could significantly impact pricing dynamics and patient access in the oncology market, though branded product market share may remain substantial due to established treatment protocols and physician familiarity.